Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01128959 · ClinicalTrials.gov registry record · Phase 3
Study to Assess the Safety and Tolerability of Intravenous Carbamazepine in Adults With Epilepsy
A Phase 3 study, sponsored by Lundbeck.
- Completed
- Registry status
- Phase 3
- Development phase
- 108
- Enrollment target
NCT01128959: Completed Phase 3 study, sponsored by Lundbeck.
NCT01128959 is a Phase 3 study that has completed, run by Lundbeck. The registered enrollment target is 108 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (86% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01128959, a Phase 3 study, has completed, sponsored by Lundbeck.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 108 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the safety and tolerability of intravenous (IV) carbamazepine (CBZ) administered as multiple 15 minute infusions and a single 5 minute infusion to adult patients with epilepsy on stable higher doses of oral CBZ.
Interventions
- DRUG Intravenous Carbamazepine (IV CBZ)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 108 participants |
| Start Date | 2010-06 |
| Est. Completion | 2013-01 |
| Phase | Phase 3 |
What the finished NCT01128959 record still lists
NCT01128959 is an interventional study that assigns participants to a tested intervention. The registered 108 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (86% lower).
The record links to 0 conditions, and to 1 intervention - of which Intravenous Carbamazepine (IV CBZ) is the first listed.
NCT01128959 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01128959 about?
NCT01128959 is a clinical study titled "Study to Assess the Safety and Tolerability of Intravenous Carbamazepine in Adults With Epilepsy". The purpose of this study is to assess the safety and tolerability of intravenous (IV) carbamazepine (CBZ) administered as multiple 15 minute infusions and a single 5 minute infusion to adult patients with epilepsy on stable higher doses of oral CBZ.
What is the current status of trial NCT01128959?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 108 participants. The study started on 2010-06. Estimated completion is 2013-01.
What interventions are being tested in trial NCT01128959?
The interventions under investigation include: Intravenous Carbamazepine (IV CBZ) (DRUG).
Who is sponsoring clinical trial NCT01128959?
This trial is sponsored by Lundbeck, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01128959's enrollment target sits among peer trials
108 1664th of 2000 higher than 335 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02703207 · 108 participants · NA
Neurocognitive and Health Impact of Sleep Apnea in Elderly Veterans With Comorbid COPD
- NCT02744677 · 108 participants · NA
COMPASSION S3 - Evaluation of the SAPIEN 3 Transcatheter Heart Valve in Patients With Pulmonary Valve Dysfunction
- NCT02781883 · 108 participants · Phase 2
Clinical Trial of BP1001 in Combination With With Venetoclax Plus Decitabine in AML
- NCT03848663 · 108 participants · NA
Visual Remapping to Aid Reading With Field Loss
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia